Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction

Clinical and Experimental Gastroenterology

Volumn 7, Issue , 2014, Pages 345-358

  Poulsen, Jakob Lykke ^a   Brock, Christina ^a,b   Olesen, Anne Estrup ^a,b   Nilsson, Matias ^a   Drewes, AsbjøRn Mohr ^a,c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

Constipation; Dysfunction; Gut; Naloxegol; Opioid antagonists; Opioids

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; ANIONIC SURFACTANT; BISACODYL; ISPAGULA; LACTULOSE; MACROGOL; MAGNESIUM; METHYLCELLULOSE; MORPHINE; NALOXEGOL; NALOXONE; OXYCODONE; PLACEBO;

BLOOD BRAIN BARRIER; CLINICAL EVALUATION; CLINICAL FEATURE; CONSTIPATION; DIGESTIVE SYSTEM DISEASE; DISEASE DURATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FIRST PASS EFFECT; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINAL SECRETION; INTESTINE INNERVATION; INTESTINE MOTILITY; NONHUMAN; OPIOID INDUCED BOWEL DYSFUNCTION; OPIOID INDUCED CONSTIPATION; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; POSTOPERATIVE ILEUS; POSTOPERATIVE PERIOD; PREVALENCE; QUALITY OF LIFE; REVIEW; SENNA; SENSORY NERVE; SYMPTOM;

EID: 84907705212     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S52097     Document Type: Review

References (105)

1. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician. 2008;11(Suppl 2):S181-S200.
2. Ji RR, Zhang Q, Law PY, Low HH, Elde R, Hökfelt T. Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J Neurosci. 1995;15(12):8156-8166.
3. Laduron PM. Axonal transport of opiate receptors in capsaicin-sensitive neurones. Brain Res. 1984;294(1):157-160.
4. Brock C, Olesen SS, Olesen AE, Frøkjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72(14):1847-1865.
5. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(Suppl 5A):11S-18S.
6. Looström H, Akerman S, Ericson D, Tobin G, Götrick B. Tramadol-induced oral dryness and pilocarpine treatment: effects on total protein and IgA. Arch Oral Biol. 2011;56(4):395-400.
7. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63(7):649-671.
8. Thorpe DM. Management of opioid-induced constipation. Curr Pain Headache Rep. 2001;5(3):237-240.
9. Tamayo AC, Diaz-Zuluaga PA. Management of opioid-induced bowel dysfunction in cancer patients. Support Care Cancer. 2004;12(9): 613-618.
10. Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician. 2013;16(1):27-40.
11. Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth. 2014;113(1):148-156.
12. Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain. 2013;154(9):1542-1550.
13. Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil. 2010;22(4):424-430.
14. Choung RS, Locke GR, Zinsmeister AR, Schleck CD, Talley NJ. Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study. Am J Gastroenterol. 2009;104(5):1199-1204.
15. Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care. 2006;23(3):229-235.
16. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ. 2001;322(7295):1154-1158.
17. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10(1):35-42.
18. Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27(12):1224-1232.
19. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372-380.
20. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7(5):R1046-R1051.
21. Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol. 2011;25 Suppl B:11B-15B.
22. Wirz S, Nadstawek J, Elsen C, Junker U, Wartenberg HC. Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose. Eur J Cancer Care (Engl). 2012;21(1):131-140.
23. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99(4):750-759.
24. Bril S, Shoham Y, Marcus J. The “mystery” of opioid-induced diarrhea. Pain Res Manag. 2011;16(3):197-199.
25. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599-608.
26. Furness J, Costa M. The Enteric Nervous System. Edinburgh: Churchill Livingstone; 1987.
27. Aziz Q, Thompson DG. Brain-gut axis in health and disease. Gastroenterology. 1998;114(3):559-578.
28. Wood JD. Enteric nervous system: sensory physiology, diarrhea and constipation. Curr Opin Gastroenterol. 2010;26(2):102-108.
29. Furness JB, Kunze WA, Bertrand PP, Clerc N, Bornstein JC. Intrinsic primary afferent neurons of the intestine. Prog Neurobiol. 1998;54(1):1-18.
30. Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs. 2007;16(2):181-194.
31. Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004;16 Suppl 2:3-16.
32. Huizinga JD, Lammers WJ. Gut peristalsis is governed by a multitude of cooperating mechanisms. Am J Physiol Gastrointest Liver Physiol. 2009;296(1):G1-G8.
33. Fioravanti B, Vanderah TW. The ORL-1 receptor system: are there opportunities for antagonists in pain therapy? Curr Top Med Chem. 2008;8(16):1442-1451.
34. Greenwood-Van Meerveld B, Gardner CJ, Little PJ, Hicks GA, Dehaven-Hudkins DL. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil. 2004;16 Suppl 2:46-53.
35. Jordan B, Devi LA. Molecular mechanisms of opioid receptor signal transduction. Br J Anaesth. 1998;81(1):12-19.
36. Sharma SK, Nirenberg M, Klee WA. Morphine receptors as regulators of adenylate cyclase activity. Proc Natl Acad Sci U S A. 1975;72(2): 590-594.
37. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16 Suppl 2:17-28.
38. Sarna SK, Otterson MF. Small intestinal amyogenesia and dysmyogenesia induced by morphine and loperamide. Am J Physiol. 1990;258(2 Pt 1):G282-G289.
39. Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage. 2008;35(1):103-113.
40. Rao SS. Constipation: evaluation and treatment of colonic and anorectal motility disorders. Gastroenterol Clin North Am. 2007;36(3): 687-711.
41. Parkman HP. Assessment of gastric emptying and small-bowel motility: scintigraphy, breath tests, manometry, and SmartPill. Gastrointest Endosc Clin N Am. 2009;19(1):49-55.
42. Maqbool S, Parkman HP, Friedenberg FK. Wireless capsule motility: comparison of the SmartPill GI monitoring system with scintigraphy for measuring whole gut transit. Dig Dis Sci. 2009;54(10):2167-2174.
43. Zhang WQ, Yan GZ, Ye DD, Chen CW. Simultaneous assessment of the intraluminal pressure and transit time of the colon using a telemetry technique. Physiol Meas. 2007;28(2):141-148.
44. Stathopoulos E, Schlageter V, Meyrat B, Ribaupierre Y, Kucera P. Magnetic pill tracking: a novel non-invasive tool for investigation of human digestive motility. Neurogastroenterol Motil. 2005;17(1):148-154.
45. Hiroz P, Schlageter V, Givel JC, Kucera P. Colonic movements in healthy subjects as monitored by a Magnet Tracking System. Neurogastroenterol Motil. 2009;21(8):838-e57.
46. Murek M, Kopic S, Geibel J. Evidence for intestinal chloride secretion. Exp Physiol. 2010;95(4):471-478.
47. Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol. 2000;62: 535-572.
48. Kunzelmann K, Mall M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev. 2002;82(1):245-289.
49. Li Y, Xiang YY, Lu WY, Liu C, Li J. A novel role of intestine epithelial GABAergic signaling in regulating intestinal fluid secretion. Am J Physiol Gastrointest Liver Physiol. 2012;303(4):G453-G460.
50. Thomas PD, Forbes A, Green J, et al. Guidelines for the investigation of chronic diarrhoea, 2nd ed. Gut. 2003;52 Suppl 5:v1-v15.
51. Eherer AJ, Fordtran JS. Fecal osmotic gap and pH in experimental diarrhea of various causes. Gastroenterology. 1992;103(2):545-551.
52. van de Kerkhof EG, Ungell AL, Sjöberg AK, et al. Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with ussing chamber preparations. Drug Metab Dispos. 2006;34(11):1893-1902.
53. Larsen R, Mertz-Nielsen A, Hansen MB, Poulsen SS, Bindslev N. Novel modified Ussing chamber for the study of absorption and secretion in human endoscopic biopsies. Acta Physiol Scand. 2001;173(2): 213-222.
54. Osbak PS, Bindslev N, Poulsen SS, Kaltoft N, Tilotta MC, Hansen MB. Colonic epithelial ion transport is not affected in patients with diverticulosis. BMC Gastroenterol. 2007;7:37.
55. Sun X, Wang X, Wang GD, et al. Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine. Dig Dis Sci. 2011;56(2):330-338.
56. Kaltoft N, Tilotta MC, Witte AB, et al. Prostaglandin E2-induced colonic secretion in patients with and without colorectal neoplasia. BMC Gastroenterol. 2010;10:9.
57. Toouli J. Sphincter of Oddi: Function, dysfunction, and its management. J Gastroenterol Hepatol. 2009;24 Suppl 3:S57-S62.
58. Penagini R, Bartesaghi B, Zannini P, Negri G, Bianchi PA. Lower oesophageal sphincter hypersensitivity to opioid receptor stimulation in patients with idiopathic achalasia. Gut. 1993;34(1):16-20.
59. Kraichely RE, Arora AS, Murray JA. Opiate-induced oesophageal dysmotility. Aliment Pharmacol Ther. 2010;31(5):601-606.
60. Thorén T, Carlsson E, Sandmark S, Wattwil M. Effects of thoracic epidural analgesia with morphine or bupivacaine on lower oesophageal motility-an experimental study in man. Acta Anaesthesiol Scand. 1988;32(5):391-394.
61. Helm JF, Venu RP, Geenen JE, et al. Effects of morphine on the human sphincter of Oddi. Gut. 1988;29(10):1402-1407.
62. Thompson DR. Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis. Am J Gastroenterol. 2001;96(4):1266-1272.
63. Wu SD, Zhang ZH, Jin JZ, et al. Effects of narcotic analgesic drugs on human Oddi’s sphincter motility. World J Gastroenterol. 2004;10(19):2901-2904.
64. Coelho JC, Senninger N, Runkel N, Herfarth C, Messmer K. Effect of analgesic drugs on the electromyographic activity of the gastrointestinal tract and sphincter of Oddi and on biliary pressure. Ann Surg. 1986;204(1):53-58.
65. Sharma SS. Sphincter of Oddi dysfunction in patients addicted to opium: an unrecognized entity. Gastrointest Endosc. 2002;55(3):427-430.
66. Bouvier M, Kirschner G, Gonella J. Actions of morphine and enkephalins on the internal anal sphincter of the cat: relevance for the physiological role of opiates. J Auton Nerv Syst. 1986;16(3):219-232.
67. Burleigh DE, D’Mello A. Neural and pharmacologic factors affecting motility of the internal anal sphincter. Gastroenterology. 1983;84(2):409-417.
68. Gregersen H. Biomechanics of the Gastrointestinal Tract. New Perspectives in Motility. Research and Diagnostics. London: Springer-Verlag; 2002:93-114.
69. McMahon BP, Frøkjaer JB, Liao D, Kunwald P, Drewes AM, Gregersen H. A new technique for evaluating sphincter function in visceral organs: application of the functional lumen imaging probe (FLIP) for the evaluation of the oesophago-gastric junction. Physiol Meas. 2005;26(5):823-836.
70. McMahon BP, Drewes AM, Gregersen H. Functional oesophago-gastric junction imaging. World J Gastroenterol. 2006;12(18):2818-2824.
71. Alqudah MM, Gregersen H, Drewes AM, McMahon BP. Evaluation of anal sphincter resistance and distensibility in healthy controls using EndoFLIP ©. Neurogastroenterol Motil. 2012;24(12):e591-e599.
72. Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011;20(8):1047-1056.
73. Herndon CM, Jackson KC, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy. 2002;22(2):240-250.
74. Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349(14):1360-1368.
75. Frantzides CT, Cowles V, Salaymeh B, Tekin E, Condon RE. Morphine effects on human colonic myoelectric activity in the postoperative period. Am J Surg. 1992;163(1):144-148; discussion 148-149.
76. Telford GL, Condon RE, Szurszewski JH. Opioid receptors and the initiation of migrating myoelectric complexes in dogs. Am J Physiol. 1989;256(1 Pt 1):G72-G77.
77. De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996;69(2):103-115.
78. Torres D, Parrinello G, Trapanese C, Licata G. Sudden severe abdominal pain after a single low dose of paracetamol/codein in a cholecystectomized patient: learning from a case report. Am J Ther. 17(4):e133-e134.
79. Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther. 2012;50(5):360-367.
80. Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain. 2000;84(1):105-109.
81. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9(12):1144-1154.
82. Burness CB, Keating GM. Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Drugs. 2014;74(3):353-375.
83. Leppert W. The place of oxycodone/naloxone in chronic pain management. Contemp Oncol (Pozn). 2013;17(2):128-133.
84. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10(2):135-144.
85. Leppert W. New treatment possibilities for opioid-induced bowel dysfunction. Pain. 2013;154(9):1491-1492.
86. Kraft MD. Methylnaltrexone, a new peripherally acting mu-opioid receptor antagonist being evaluated for the treatment of postoperative ileus. Expert Opin Investig Drugs. 2008;17(9):1365-1377.
87. Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35(5): 458-468.
88. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332-2343.
89. Schmidt WK. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg. 2001;182(Suppl 5A):27S-38S.
90. Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction-a 21-day treatment-randomized clinical trial. J Pain. 2005;6(3):184-192.
91. Camilleri M. Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil. 2005;17(2):157-165.
92. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002;54(4):459-476.
93. Belsey JD, Geraint M, Dixon TA. Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation. Int J Clin Pract. 2010;64(7):944-955.
94. The PubChem Project-[homepage on the Internet]. Naloxegol. National Center for Biotechnology Information. Available at: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=56959087#itabs-2d. Accessed July 10, 2014.
95. Wirz S, Klaschik E. Management of constipation in palliative care patients undergoing opioid therapy: is polyethylene glycol an option? Am J Hosp Palliat Care. 2005;22(5):375-381.
96. Eldon M, Song D, Neumann T. Oral NKTR-118 (oral PEG-naloxol), a PEGylated derivative of naloxone; demonstration of selective peripheral opioid antagonism after oral administration. Poster presented at: The American Academy of Pain Management 18th Annual Clinical Meeting; September 27-30, 2007; Las Vegas, NV.
97. Gottfridsson C, Carlson G, Lappalainen J, Sostek M. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo-and positive-controlled crossover thorough QT/QTc study in healthy volunteers. Clin Ther. 2013;35(12):1876-1883.
98. Paaschen H van, Sahner D, Marcantonio A, Eldon MA. Results from a phase 1, double-blind, randomized, placebo-controlled. Multiple-dose study evaluating the safety, tolerability, and pharmacokinetics of oral doses of NKTR-118 (PEG-Naloxol). J Pain. 2008;9(4, Supplement 2):28. Available from http://www.nektar.com/pdf/pipeline/NKTR-118/NKTR-118_Phase_1_APS_Poster_20080507.pdf. Accessed August 19, 2014.
99. Odinecs A, Song Y, Harite S, Lee MG, Kugler AR, Eldon MA. NKTR-118, an oral peripheral opioid antagonist, has low potential for drug-drug interactions. Poster presented at: The American College of Clinical Pharmacology 38th Annual Meeting; September 13-15, 2009; San Antonio, TX.
100. Bui K, She F, Sostek M. The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. Epub 2014 Jun 19.
101. Bui K, She F, Sostek M. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. Epub 2014 Jun 19.
102. US Food and Drug Administration. Naloxegol NDA 204-760 Briefing Document for the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). Washington DC: US Food and Drug Administration. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM400209.pdf. Accessed August 14, 2014.
103. Neumann T, Paaschen H Van, Marcantonio A, Song D, Kugler AR, Eldon MA. Evaluation of PEG-Naloxol (NKTR-118) as an oral peripheral opioid antagonist in healthy male subjects: a double-blind, placebo-controlled, dose escalation crossover study. Poster presented at: The American College of Clinical Pharmacology 36th Annual Meeting; September 9-11, 2007; San Francisco, CA.
104. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387-2396.
105. Olesen AE, Drewes AM. Validated tools for evaluating opioid-induced bowel dysfunction. Adv Ther. 2011;28(4):279-294.